Long COVID Treatment

Long COVID Treatment Menu

BOB体育 COVID RESTORE Treatment Program

The BOB体育 COVID RESTORE program supports COVID "long-haulers". Long COVID patients have persistent symptoms that last 4 weeks or longer after infection. Our comprehensive interdisciplinary program is available for people with Long COVID. Long COVID is also called PASC (Persistent Sequelae of SARS-CoV-2).

Referrals and Appointments

Ask your physician if you qualify for this PASC/Long COVID program. You can have them fax a referral to 352.627.4170.
You must have been seen in-person by a primary care provider (PCP) within the last month to be referred.

What to Expect When Calling for an Appointment

Call 352.265.WELL (9355) to schedule an appointment.
If you do not live in the Gainesville area, you may request a telemedicine appointment. We'll give you instructions on how to access your telemedicine appointment using MyUFHealth.
Physician visits are covered by insurance. You may be asked to verify your insurance coverage for other services. These services can include rehabilitation, psychology and/or acupuncture.
Before your first appointment, we'll ask you to complete a questionnaire on MyUFHealth. This questionnaire with help us better asses your needs.

COVID Research Studies 锘�

Interested in future Long COVID studies at UF/BOB体育? Visit for more information.

Addition of Pembrolizumab to Usual Intravesical Gemcitabine for Treatment of BCG-Unresponsive NMIBC

This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as鈥�

Investigator: Paul L Crispen
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

TREAT-MS

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early鈥�

Investigator: Torge Rempe
Status: Accepting Candidates
Ages: 18 Years - 60 Years
Sexes: All

Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST

This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.

Investigator: Joanne Lagmay
Status: Accepting Candidates
Ages: 12 Years - 99 Years
Sexes: All

BOB体育